Related Experiment Video
Updated: Sep 10, 2025
05:26
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
9.4K
Outcomes Associated With SGLT2 Inhibitor Use Following Acute Myocardial Infarction Without Heart Failure: A
Rochell Issa1,2, Tess Calcagno1, Tyler Canova3
1Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, OH, USA.
Angiology
|August 25, 2025
Summary
Sodium-glucose co-transporter-2 inhibitors (SGLT2i) reduced major adverse cardiovascular events and all-cause mortality in acute myocardial infarction patients without heart failure. SGLT2i use also lowered bleeding risk, suggesting cardioprotective benefits.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are established treatments for heart failure and diabetes.
- Their role in acute myocardial infarction (AMI) patients without prior heart failure is less understood.
Purpose of the Study:
- To evaluate the association between SGLT2i use and cardiovascular outcomes in patients with AMI but no history of heart failure.
Main Methods:
- Retrospective propensity-matched cohort study using the TriNetX U.S. Collaborative Network.
- 1440 matched patients (720 SGLT2i+ vs. 720 SGLT2i-) with preserved ejection fraction and no prior heart failure were analyzed.
- Primary outcome: major adverse cardiovascular events (MACE) at 1 year.
Main Results:
- SGLT2i use was associated with a significant reduction in MACE (17.4% vs. 22.0%; OR 0.746; P=.028).
- All-cause mortality was significantly lower in SGLT2i users (3.1% vs. 7.6%; OR 0.389; P<.001).
- SGLT2i use was also linked to a lower risk of major bleeding.
Conclusions:
- SGLT2 inhibitors may offer cardioprotective benefits post-MI in patients without heart failure, though residual confounding is possible.
- The novel finding of reduced bleeding warrants further investigation in prospective studies.
More Related Videos
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
01:23Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
01:28Acute Coronary Syndrome IV: Interprofessional Care
26
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
291
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
291
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:30Acute Coronary Syndrome I: Introduction
72
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
72